Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Enhanced Lab Data Management and AI Critical to Labs of the Future, Finds Survey

By LabMedica International staff writers
Posted on 13 Jun 2025

Data plays a key role in the transformation of today’s digital laboratories, acting both as a key challenge and a catalyst for innovation, as revealed by a survey of over 150 scientists. More...

Managing and navigating data overload emerged as the most pressing issue affecting lab workflows. Yet this influx of data also presents a significant opportunity: participants identified AI’s ability to process and derive insights from the massive quantities of data generated by instruments, experiments, and other sources as its most valuable application going forward. This contrast positions data not only as a complication but also as the essential ingredient driving future AI-powered advancements in the lab. The survey, conducted by Titian Software (Westborough, MA, USA)—provider of the Mosaic sample management platform—and Labguru (Westborough, MA, USA), a provider of LIMS, ELN, inventory, and data management solutions, explores the evolving digital landscape of lab operations in the life sciences field.

Despite the anticipated transformative impact of AI and machine learning on laboratory practices, many labs are still not fully equipped to capitalize on these technologies. Foundational hurdles persist, with a strong focus on streamlining inventory management and reducing reliance on manual tasks. A notable 65% of respondents highlighted reagent and supply inventory management as the primary technology they aim to implement. Additionally, 77% believe that automation will be the leading driver of change by 2026, emphasizing the need to resolve operational bottlenecks before labs can integrate more advanced technologies. These trends held consistently across all lab types—from large pharmaceutical companies to emerging startups. Although interest in innovative tools like robotics and AI continues to grow, just 15% of labs report being fully digitized, and nearly 50% still depend on manual procedures.

Looking ahead, 45% of those surveyed plan to roll out advanced lab technologies such as AI within the next two years, yet 25% either have no immediate plans or expect implementation will take more than five years. This divide signals a critical transition period where foundational improvements must come first to unlock AI’s full capabilities. The main promise of AI lies in its capacity to interpret the vast and complex volumes of data generated in labs. Around 24% of respondents named handling data from experiments and instruments as the most important role for AI in lab operations over the next five years. Furthermore, 54% pointed to data overload and management as a central force prompting change. The issue isn’t just about the quantity of data; it’s the complexity spanning various modalities, which adds strain in areas such as automation, storage, acquisition, compliance, and regulatory adherence. As AI shifts from theoretical promise to practical necessity, the life sciences sector is on the verge of significant transformation. Although organizations generally recognize AI’s potential to streamline operations, speed up discovery, and clarify complex datasets, overall digital maturity varies widely, and challenges like data fragmentation and doubt around AI-generated results continue to hinder progress.

"Labs today are generating more data than ever before, but without the right systems in place, that data becomes a burden instead of a benefit," said Keith Hale, Group Chief Executive Officer at Titian Software and Labguru. "Better data practices and smarter sample and inventory management are essential not only for improving day-to-day operations but also for setting the stage for more advanced capabilities. AI cannot deliver real, meaningful benefit without connected and well-managed data. That is where we come in. By helping labs streamline and structure their operations and data management today, we can enable the power of AI to transform the labs of tomorrow."

Related Links:
Titian Software
Labguru


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Slide Scanner System
NanoZoomer S540MD
Hematology Consumables
Bioblood Devices
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.